Egyptian International Pharmaceutical Industries Co 2022 Annual Report
The report highlights EIPICO's performance for the fiscal year ended December 31, 2022. The company achieved record production exceeding EGP 4 billion, representing a 16.6% growth, and maintained its leading position in the Egyptian pharmaceutical market. EIPICO expanded its global footprint to 74 countries, with export sales reaching USD 52.6 million. Key strategic developments included progress on the EIPICO 3 factory for biologicals and biosimilars, and the launch of the EIPICO Pharma 4.0 digital transformation project. Additionally, the company aligned its operations with 12 UN Sustainable Development Goals and maintained a 6% employment rate for persons with disabilities.
Company: Egyptian International Pharmaceutical Industries Co
Sector: Manufacturing
Country: Egypt
Year: 2022
Type: Annual Report
Pages: 143
Back to company
Egyptian International Pharmaceutical Industries Co
Annual Report (Arabic edition)
The report highlights EIPICO's performance for the fiscal year ended December 31, 2022. The company achieved record production exceeding EGP 4 billion, representing a 16.6% growth, and maintained its leading position in the Egyptian pharmaceutical market. EIPICO expanded its global footprint to 74 countries, with export sales reaching USD 52.6 million. Key strategic developments included progress on the EIPICO 3 factory for biologicals and biosimilars, and the launch of the EIPICO Pharma 4.0 digital transformation project. Additionally, the company aligned its operations with 12 UN Sustainable Development Goals and maintained a 6% employment rate for persons with disabilities.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Annual Report
Language
Arabic
Pages
File Size
Standards & Assurance
No data available
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Employees